Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
NCT00346073
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2337
Enrollment
INDUSTRY
Sponsor class
Conditions
Acellular Pertussis
Diphtheria
Tetanus
Interventions
BIOLOGICAL:
Boostrix™
BIOLOGICAL:
ADACEL®
Sponsor
GlaxoSmithKline